Serafin Andrea, Ruocco Valeria, Cellini Alessandro, Angotzi Francesco, Bonaldi Laura, Trentin Livio, Visentin Andrea
Hematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, Padova, Italy.
Br J Haematol. 2025 Mar;206(3):832-841. doi: 10.1111/bjh.19986. Epub 2025 Jan 6.
Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease characterised by the uncontrolled proliferation of mature lymphocytes. A subset of CLL patients harbouring complex karyotype (CK) presents with poor prognosis and limited treatment options. This review aims to discuss the current understanding of such patient subset, including its molecular landscape, diagnostic approaches, treatment modalities and emerging therapies. Furthermore, it outlines strategies for personalised management to improve clinical outcomes in this challenging patient population.
慢性淋巴细胞白血病(CLL)是一种异质性疾病,其特征为成熟淋巴细胞的不受控制增殖。一部分具有复杂核型(CK)的CLL患者预后较差且治疗选择有限。本综述旨在讨论对这类患者亚群的当前认识,包括其分子格局、诊断方法、治疗方式和新兴疗法。此外,还概述了个性化管理策略,以改善这一具有挑战性的患者群体的临床结局。